Crossmark

Efficacy of the nano curcumin supplementation on fibrosis, steatosis, inflammatory and metabolic status of liver fibrosis patients with non-alcoholic fatty liver origin: a study protocol for a double-blind randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s40795-026-01252-0

Published Online: 2026-02-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gerami, Hadis

Mozaffari-Khosravi, Hassan

Mansour, Asieh

Sohrabpour, Amir Ali

Poustchi, Hossein

Taheri, Amir Pejman Hashemi

Jaafari, Mahmoud Reza

Jambarsang, Sara

Khayyatzadeh, Sayyed Saeid https://orcid.org/0000-0002-9133-7340
License Information

Text and Data Mining valid from 2026-02-02

Version of Record valid from 2026-03-03
More Information

Article History

Received: 23 August 2024

Accepted: 8 January 2026

First Online: 2 February 2026

Declarations

:

: This study will conducted according to the principles of the declaration of Helsinki. The current clinical trial has been approved by the research ethics committee (REC) of Shahid Sadoughi University of Medical Sciences (Yazd, Iran) (REC approval ID: IR. SSU. SPH.REC. 1401. 157). All participants will provide informed written consent before enrolment in the study (Supplementary). The intervention will be designed not to interfere with the routine treatment of patients.

: After finishing the study, the results of the study will be published.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below